<DOC>
	<DOCNO>NCT00722215</DOCNO>
	<brief_summary>The number people kidney problem increase rapidly , related part increase prevalence diabetes . Patients kidney problem tend protein leak urine ( proteinuria ) . Both proteinuria kidney disease associate increase risk heart disease . Reducing proteinuria important treatment goal people kidney problem . Endothelin chemical produce blood vessel kidney . Higher normal level endothelin think contribute progression kidney disease proteinuria . By use drug block effect endothelin ( 'endothelin receptor antagonist ' ) hopefully reduce . The purpose study ascertain whether endothelin receptor antagonist improve kidney function reduce proteinuria commonly use drug .</brief_summary>
	<brief_title>Endothelin Receptor Antagonism Proteinuric Nephropathy</brief_title>
	<detailed_description>Response ETA Receptor Antagonism/Nifedipine/Placebo Prior study visit subject ask refrain alcohol 24 hour . Tea coffee permit least 12 hour visit . Studies conduct quiet , temperature-controlled room . On arrival Clinical Research Centre study day , brief medical enquiry examination confirm ongoing suitability subject study . An intravenous cannula insert antecubital fossa arm . We develop basic protocol describe fully previous study allow u measure systemic haemodynamics well validate technique bioimpedance renal function standard para-aminohippurate ( PAH ; renal blood flow ) inulin ( glomerular filtration rate ) clearance study . Urinary protein excretion measure collect urine 30 minute time period . To ascertain contribution renal haemodynamics change protein excretion renal blood flow glomerular filtration rate measure . In addition , blood urine also assay sodium , creatinine osmolality allow calculation fractional excretion sodium free water clearance . Systemic haemodynamic monitoring perform 15 minute interval drug/placebo administration 30 minute interval outwith period .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<mesh_term>Endothelin A Receptor Antagonists</mesh_term>
	<mesh_term>cyclo ( Trp-Asp-Pro-Val-Leu )</mesh_term>
	<criteria>Male female Age 1870 Body mass index &lt; 35 Blood pressure &lt; 160/110 mmHg CKD stage 25 per K/DOQI classification Proteinuria one follow category : 0.31.5 , &gt; 1.53.0 , &gt; 3.06.0 g/24hrs Normal serum albumin Subject age legal consent , mentally legally incapacitated History multiple and/or severe allergic reaction drug ( include study drug ) , food The subject donate blood ( 450 ml ) within last 4 week Past present drug alcohol abuse include intravenous drug abuse time Participation another clinical trial within 1 month Considered high risk HIV hepatitis B Pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>Endothelin antagonist</keyword>
	<keyword>Chronic kidney disease</keyword>
	<keyword>Proteinuria</keyword>
	<keyword>Cardiovascular disease</keyword>
	<keyword>Blood pressure</keyword>
	<keyword>Arterial stiffness</keyword>
	<keyword>Endothelial function</keyword>
</DOC>